Abstracts tagged "quality of life"

Abstract Number: 1836 • ACR Convergence 2023
Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium
Jennifer Rogers¹, Megan Clowse² and Amanda Eudy³, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University, Raleigh, NC
Background/Purpose: Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are…
Abstract Number: 2212 • ACR Convergence 2023
Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis
Styliani Tsiami¹, Kalliopi Klavdianou², Imke Redeker³, Yaren Elif Özdemir⁴, Philipp Sewerin¹, David Kiefer¹, Ioana Andreica⁵, Uta Kiltz⁶ and Xenofon Baraliakos⁴, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²Asklepieion' General Hospital, Department of Rheumatology, Voula, Kaisariani Athens, Greece, ³Ruhr Universität Bochum, Bochum, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: In axial spondyloarthritis (axSpA), assessment of disease activity and physical function in clinical studies relies on patient-reported outcomes (PRO) such as patient's global, BASDAI,…
Abstract Number: PP15 • ACR Convergence 2023
Toward a Frontier Beyond the Barriers of Position and Prejudice
Noriko Okochi¹, Eiji Oishi², Yuki Kojima³, Noro Takashi³, Mika Ishiguro³, Toshiko Ito-Ihara⁴ and YOSHIHIRO ARIMURA⁵, ¹Rheumatic Disease and Vasculitis Support Network Japan, Institute of Neuropsychiatry, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, UBE Frontier University, Yamaguchi, Japan, ³Rheumatic Disease and Vasculitis Support Network Japan, Shinagawa-Ku, Tokyo, Japan, ⁴Kyoto Prefectural University of Medicine, Rheumatic Disease and Vasculitis Support Network Japan, Kyoto, Japan, ⁵Kyorin University School of Medicine, Kichijoji Asahi Hospital, Rheumatic Disease and Vasculitis Support Network Japan, Mitaka-Shi, Tokyo, Japan
Background/Purpose: In Japan, firm boundaries exist between people from different walks of life surrounding diseases. 【Patients】Some patients are unable to assert themselves before doctors who…
Abstract Number: 0146 • ACR Convergence 2023
Sexual Health and Self-Perception in Rheumatologic Patients: Has Your Rheumatologist Ever Talked to You About Sexual Health?
Luis Vega Sevilla¹, Griselda Serna-Peña², Diana Paola Flores-Gutierrez³, Jesus Alberto Cardenas-De la Garza⁴, Dionicio A. Galarza-Delgado⁵ and Ivan Hernandez Galarza⁶, ¹Hospital Universitario UANL, Garcia, Mexico, ²Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁵Hospital Universitario UANL, Monterrey, Mexico, ⁶University Hospital, UANL, San Pedro Garza Garcia, Mexico
Background/Purpose: There's a high prevalence of sexual dysfunction (SD) in patients with rheumatic diseases (RD). Studies show that it goes from a 36% to a…
Abstract Number: 0525 • ACR Convergence 2023
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Marina Nighat Magrey¹, Marleen van de Sande², Maxime Breban³, Filip Van den Bosch⁴, Carmen Fleurinck⁵, Ute Massow⁶, Natasha De Peyrecave⁷, Thomas Vaux⁸, Xenofon Baraliakos⁹ and Helena Marzo-Ortega¹⁰, ¹Case Western Reserve University, University Hospitals, Cleveland, OH, ²Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ³CHU Ambroise-Paré, Boulogne-Billancourt, Paris, France, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Slough, United Kingdom, ⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ¹⁰NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…
Abstract Number: 1170 • ACR Convergence 2023
Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…
Abstract Number: 1838 • ACR Convergence 2023
The Burden of Dysautonomia in Patients Suffering from Pathologies Associated with Generalized Joint Hypermobility
Alizée Perrein¹, Fabien Pontille¹, Paul Decker², david Attali³, Thomas Moulinet⁴ and Roland Jaussaud⁵, ¹Département de Médecine interne et immunologie clinique, Université de Lorraine / CHRU de Nancy, Vandoeuvre-les-Nancy, France, ²Nancy hospital, France, Nancy, France, ³Université Paris Cité, Laboratoire Psychopathologie et Processus de Santé, Boulogne-Billancourt, France, ⁴Department of Internal Medicine, Centre hospitalier universitaire de Nancy, Nancy, France, ⁵Département de Médecine interne et immunologie clinique, Université de Lorraine / CHRU de Nancy, Vandoeuvre Les Nancy, France
Background/Purpose: Hypermobility spectrum disorders (HSD) and hypermobile Ehlers Danlos syndrome (hEDS) are among the conditions associated with generalized joint hypermobility (GJH). Alongside myofascial and skeletal…
Abstract Number: 2249 • ACR Convergence 2023
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Dafna Gladman¹, Laura Coates², Maarten de Wit³, Alexis R Ogdie⁴, Ana-Maria Orbai⁵, Barbara Ink⁶, Vanessa Taieb⁷, Jérémy Lambert⁸ and Laure Gossec⁹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Oxford, Oxford, United Kingdom, ³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Irigny, France, ⁹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: The PsA Impact of Disease‑12 (PsAID‑12) questionnaire is a patient (pt)-reported outcome measure assessing the impact of PsA on 12 physical, social, and psychological…
Abstract Number: PP17 • ACR Convergence 2023
Utilizing Support Networks to Improve Patient Outcomes
Brian Vogel, Lupus and Allied Diseases Association, Inc., San Diego, CA
Background/Purpose: In 2006, I realized I was gay and identified as LGBTQIA but did not come out. In 2008, I began experiencing chronic widespread pain,…
Abstract Number: 026 • 2023 Pediatric Rheumatology Symposium
Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort
Sophie Stefancic, Amanda Robinson, Haley Havrilla, Samantha Branton, Vibha Sood and Kathryn Torok, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gastrointestinal (GI) manifestations in juvenile onset systemic sclerosis (jSSc) reflect adult disease with a range of involvement along the GI tract, including oropharyngeal dysphagia…
Abstract Number: 030 • 2023 Pediatric Rheumatology Symposium
International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update
Christina ZIgler¹, Debra Henke², Clare Pain³, Hanna Lythgoe³, Kaveh Ardalan², Kathryn Torok⁴ and Suzanne Li⁵, ¹Duke, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare condition causing inflammation and fibrosis that may impair health-related quality of life (HRQoL). Recent studies demonstrate extracutaneous…
Abstract Number: 042 • 2023 Pediatric Rheumatology Symposium
Prevalence of Chronic Pain in Childhood-onset Systemic Lupus Erythematosus and Juvenile Dermatomyositis
Sara Patrizi¹, Susmita Kashikar-Zuck², CARRA Registry Investigators³, Mekibib Altaye⁴ and Jennifer Weiss⁵, ¹Stanford Medicine, Children's Health, Palo Alto, CA, ²University of Cincinnati College of Medicine; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³CARRA, Washington, DC, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Pediatric Rheumatology, Hackensack Meridian School of Medicine, Hackensack University Medical Center, Hackensack, New Jersey, Hackensack, NJ
Background/Purpose: The prevalence, severity and impact of chronic pain in pediatric patients with autoimmune diseases such as childhood onset SLE (cSLE) and juvenile dermatomyositis (JDM)…
Abstract Number: 052 • 2023 Pediatric Rheumatology Symposium
Extreme Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA): A Discrete Group of Patients
Yoel Levinsky¹, Rotem Tal², Liora Harel², Shoval Shoham³, Sabreen Abu Ahmad⁴, Yonatan Butbul Aviel⁵, Gil Amarilyo² and Mor Broide³, ¹Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ²Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁴Ruth Rappaport Children's Hospital, Rambam Health Care, Haifa, Israel, ⁵Rambam Medical center, Haifa, Israel
Background/Purpose: Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is the most common periodic fever syndrome in children; by definition, episodes occur every…
Abstract Number: 0285 • ACR Convergence 2022
Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
Roberto Felice Caporali¹, Jayeshkumar Patel², Oliver Howell³, sander strengholt⁴, Hannah Jones³ and Peter Taylor⁵, ¹University of Milan, Milano, Italy, ²AbbVie, Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴AbbVie, Inc., Abcoude, Netherlands, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor, is a newly approved advanced therapy for patients (pts) with rheumatoid arthritis (RA), thus real-world evidence is lacking.…
Abstract Number: 1299 • ACR Convergence 2022
Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children
Jo-Anne Marcuz¹, Brian Feldman², Y. Ingrid Goh³, Niina Kim⁴, Piya Lahiry⁵, Deborah Levy², Elizaveta Limenis⁶, Jeanine McColl⁷, Christine O'Brien⁸, Susan Paetkau⁴, Shirley Tse², Kristi Whitney⁸ and Ronald Laxer², ¹Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children; Department of Pediatrics, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children with significant morbidity that extends into adulthood. Despite advances in effective…

« Previous Page
1
…
8
9
10
11
12
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].